Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma
Cancer Communications · 2024-02 · 44 (2) · 226-250
DOI: 10.1002/cac2.12513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 24.12.2023. Verfasst von Weiren Liu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and C…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Beijing Nova Program.
Abstract (Originalsprache)
Background
Intrahepatic cholangiocarcinoma (iCCA) is a highly heterogeneous and lethal hepatobiliary tumor with few therapeutic strategies. The metabolic reprogramming of tumor cells plays an essential role in the development of tumors, while the metabolic molecular classification of iCCA is largely unknown. Here, we performed an integrated multiomics analysis and metabolic classification to depict differences in metabolic characteristics of iCCA patients, hoping to provide a novel perspective to understand and treat iCCA.
Methods
We performed integrated multiomics analysis in 116 iCCA samples, including whole‐exome sequencing, bulk RNA‐sequencing and proteome analysis. Based on the non‐negative matrix factorization method and the protein abundance of metabolic genes in human genome‐scale metabolic models, the metabolic subtype of iCCA was determined. Survival and prognostic gene analyses were used to compare overall survival (OS) differences between metabolic subtypes. Cell proliferation analysis, 5‐ethynyl‐2'‐deoxyuridine (EdU) assay, colony formation assay, RNA‐sequencing and Western blotting were performed to investigate the molecular mechanisms of diacylglycerol kinase α (DGKA) in iCCA cells.
Results
Three metabolic subtypes (S1‐S3) with subtype‐specific biomarkers of iCCA were identified. These metabolic subtypes presented with distinct prognoses, metabolic features, immune microenvironments, and genetic alterations. The S2 subtype with the worst survival showed the activation of some special metabolic processes, immune‐suppressed microenvironment and Kirsten rat sarcoma viral oncogene homolog ( KRAS )/AT‐rich interactive domain 1A ( ARID1A ) mutations. Among the S2 subtype‐specific upregulated proteins, DGKA was further identified as a potential drug target for iCCA, which promoted cell proliferation by enhancing phosphatidic acid (PA) metabolism and activating mitogen‐activated protein kinase (MAPK) signaling.
Conclusion
Via multiomics analyses, we identified three metabolic subtypes of iCCA, revealing that the S2 subtype exhibited the poorest survival outcomes. We further identified DGKA as a potential target for the S2 subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, P. R. China.
- Research Unit of Liver cancer Recurrence and Metastasis, Chinese Academy of Medical Sciences, Beijing, P. R. China.
- State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, P. R. China.
ORCID-Profile: Qianfu Zhao, Guiqi Zhu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Beijing Nova Program
- Shanghai Municipal Science and Technology Major Project
- Shanghai Municipal Key Clinical Specialty, CAMS Innovation Fund for Medical Sciences
- State Key Laboratory of Proteomics
Zitieren
APA
Liu, W., Wang, H., Zhao, Q., Tao, C., Qu, W., Hou, Y., Huang, R., Sun, Z., Zhu, G., Jiang, X., Fang, Y., Gao, J., Wu, X., Yang, Z., Ping, R., Chen, J., Yang, R., Chu, T., Zhou, J., …, & Shi, Y. (2024). Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma. Cancer Communications, 44(2), 226-250. https://doi.org/10.1002/cac2.12513
Vancouver
Liu W, Wang H, Zhao Q, Tao C, Qu W, Hou Y, et al. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma. Cancer Communications. 2024;44(2):226-250. doi:10.1002/cac2.12513
BibTeX
@article{Liu2024,
author = {Liu, Weiren and Wang, Huqiang and Zhao, Qianfu and Tao, Chenyang and Qu, Weifeng and Hou, Yushan and Huang, Run and Sun, Zimei and Zhu, Guiqi and Jiang, Xifei and Fang, Yuan and Gao, Jun and Wu, Xiaoling and Yang, Zhixiang and Ping, Rongyu and Chen, Jiafeng and Yang, Rui and Chu, Tianhao and Zhou, Jian and Fan, Jia and Tang, Zheng and Yang, Dong and Shi, Yinghong},
title = {Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma},
journal = {Cancer Communications},
year = {2024},
volume = {44},
number = {2},
pages = {226--250},
doi = {10.1002/cac2.12513}
}
EUVIMED